Loading
A phase 2 trial of Belantamab mafodotin, Dexamethasone, Pomalidomide in multiple myeloma, run by GlaxoSmithKline, now recruiting.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) is a phase 2 interventional study registered as NCT07227311 by GlaxoSmithKline, with 200 participants planned, started 2026-04-15 and due to reach its primary completion in 2030-08-30. Interventions recorded: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Belantamab mafodotin, Pomalidomide, Bortezomib, GSK.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
Shares Belantamab mafodotin, Bortezomib, GSK, Dexamethasone.
Shares Belantamab mafodotin, GSK, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Carfilzomib, Pomalidomide, Bortezomib, Dexamethasone.
Shares Belantamab mafodotin, Pomalidomide, GSK, Dexamethasone.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/